CY2505B1 - Quinoline derivatives as nk3 antagonists - Google Patents
Quinoline derivatives as nk3 antagonistsInfo
- Publication number
- CY2505B1 CY2505B1 CY0400083A CY0400083A CY2505B1 CY 2505 B1 CY2505 B1 CY 2505B1 CY 0400083 A CY0400083 A CY 0400083A CY 0400083 A CY0400083 A CY 0400083A CY 2505 B1 CY2505 B1 CY 2505B1
- Authority
- CY
- Cyprus
- Prior art keywords
- antagonists
- quinoline derivatives
- quinoline
- derivatives
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9524104.8A GB9524104D0 (en) | 1995-11-24 | 1995-11-24 | Novel compounds |
| PCT/EP1996/005209 WO1997019927A1 (en) | 1995-11-24 | 1996-11-22 | Quinoline derivatives as nk3 antagonists |
| CA002238171A CA2238171C (en) | 1995-11-24 | 1998-05-21 | Quinoline derivatives as nk3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY2505B1 true CY2505B1 (en) | 2005-12-23 |
Family
ID=31496493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY0400083A CY2505B1 (en) | 1995-11-24 | 2004-11-22 | Quinoline derivatives as nk3 antagonists |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6743804B2 (enExample) |
| EP (1) | EP0874827B1 (enExample) |
| JP (1) | JP2000512614A (enExample) |
| CA (1) | CA2238171C (enExample) |
| CY (1) | CY2505B1 (enExample) |
| DE (1) | DE69628334T2 (enExample) |
| ES (1) | ES2200080T3 (enExample) |
| GB (1) | GB9524104D0 (enExample) |
| WO (1) | WO1997019927A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037922B1 (en) | 2000-03-10 | 2006-05-02 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
| ATE247652T1 (de) | 1999-03-29 | 2003-09-15 | Neurogen Corp | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden |
| CA2375920A1 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Compounds |
| WO2001029025A2 (en) | 1999-10-19 | 2001-04-26 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| US6960590B2 (en) | 2000-10-17 | 2005-11-01 | Merck & Co. Inc. | Orally active salts with tyrosine kinase activity |
| GB0028964D0 (en) * | 2000-11-28 | 2001-01-10 | Smithkline Beecham Spa | Novel compounds |
| WO2003037252A2 (en) | 2001-10-30 | 2003-05-08 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1541149A1 (en) * | 2002-06-26 | 2005-06-15 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| BR122018074353B8 (pt) | 2003-01-28 | 2023-05-02 | Ironwood Pharmaceuticals Inc | composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos |
| RU2229475C1 (ru) * | 2003-03-06 | 2004-05-27 | ООО "Исследовательский институт химического разнообразия | 6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека |
| TW201018662A (en) | 2005-12-12 | 2010-05-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US20090118135A1 (en) * | 2007-06-08 | 2009-05-07 | The Burnham Institute | Methods and compounds for regulating apoptosis |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| CN103819403B (zh) | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| RU2015107019A (ru) | 2012-08-21 | 2016-10-10 | Эрделикс Инк. | Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| CN105392483B (zh) | 2013-04-12 | 2019-03-15 | 阿德利克斯公司 | 用于抑制磷酸盐转运的nhe3结合化合物和方法 |
| BR112015026519A2 (pt) | 2013-04-19 | 2017-07-25 | Astrazeneca Ab | composto antagonista do receptor nk3 (nk3ra) para uso em um método destinado ao tratamento de síndrome do ovário policístico (sop) |
| PL3004138T3 (pl) | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
| ES2726927T3 (es) * | 2014-07-08 | 2019-10-10 | Dow Agrosciences Llc | Proceso para la preparación de ácidos 3-hidroxipicolínicos |
| WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
| EA201991676A1 (ru) | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | Ингибиторы nhe-опосредованного антипорта |
| KR20240090875A (ko) | 2017-01-09 | 2024-06-21 | 알데릭스, 인코포레이티드 | 위장관 장애를 치료하는 데 유용한 화합물 |
| CN113194948A (zh) * | 2018-11-15 | 2021-07-30 | 国立大学法人九州大学 | Il-31介导性疾病的预防或治疗剂及医药组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2538388B1 (fr) * | 1982-12-24 | 1985-06-21 | Pharmuka Lab | Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments |
| ES2149767T5 (es) * | 1991-09-20 | 2005-06-16 | Glaxo Group Limited | Nuevo uso medico para antagonistas de taquiquininas. |
| DE69315920T2 (de) * | 1992-09-04 | 1998-06-10 | Takeda Chemical Industries Ltd | Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung |
| TW263498B (enExample) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| DE69531458T2 (de) * | 1994-05-27 | 2004-08-05 | Glaxosmithkline S.P.A. | Chinolinderivate als tachykinin nk3 rezeptor antagonisten |
| IT1270615B (it) * | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
-
1995
- 1995-11-24 GB GBGB9524104.8A patent/GB9524104D0/en active Pending
-
1996
- 1996-11-22 DE DE69628334T patent/DE69628334T2/de not_active Expired - Lifetime
- 1996-11-22 EP EP96939926A patent/EP0874827B1/en not_active Expired - Lifetime
- 1996-11-22 WO PCT/EP1996/005209 patent/WO1997019927A1/en not_active Ceased
- 1996-11-22 JP JP09520159A patent/JP2000512614A/ja not_active Ceased
- 1996-11-22 ES ES96939926T patent/ES2200080T3/es not_active Expired - Lifetime
-
1998
- 1998-05-21 CA CA002238171A patent/CA2238171C/en not_active Expired - Fee Related
-
2002
- 2002-05-07 US US10/140,452 patent/US6743804B2/en not_active Expired - Fee Related
-
2004
- 2004-11-22 CY CY0400083A patent/CY2505B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0874827B1 (en) | 2003-05-21 |
| CA2238171C (en) | 2008-07-22 |
| GB9524104D0 (en) | 1996-01-24 |
| US20030195204A1 (en) | 2003-10-16 |
| CA2238171A1 (en) | 1999-11-21 |
| WO1997019927A1 (en) | 1997-06-05 |
| ES2200080T3 (es) | 2004-03-01 |
| US6743804B2 (en) | 2004-06-01 |
| DE69628334T2 (de) | 2004-02-19 |
| DE69628334D1 (de) | 2003-06-26 |
| JP2000512614A (ja) | 2000-09-26 |
| EP0874827A1 (en) | 1998-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2616495A (en) | Quinoline derivatives as tachykinin nk3 receptor antagonists | |
| PL326967A1 (en) | Quinoline derivatives | |
| GR3036346T3 (en) | BENZO[g]QUINOLINE DERIVATIVES | |
| HU9601176D0 (en) | Adhesion-receptor antagonists | |
| IL128141A0 (en) | Tetrahydroquinoline derivatives as eaa antagonists | |
| HUP9903584A3 (en) | Salts of quinoline derivatives as nk3 antagonists | |
| SI0854867T1 (en) | Tetrahydroquinolines as nmda antagonists | |
| IL140062A0 (en) | Tetrahydroquinoline derivatives as glycine antagonists | |
| GB9404378D0 (en) | Quinoline derivatives | |
| ZA954269B (en) | Quinoline derivatives | |
| GB9508786D0 (en) | Substituted heterocycles | |
| GB9413150D0 (en) | Quinoline derivatives | |
| GB9402275D0 (en) | Quinoline derivatives | |
| IL127376A0 (en) | Benzo (g) quinoline derivatives | |
| GR3033237T3 (en) | Quinoline derivatives as leukoriene antagonists. | |
| SI0940391T1 (en) | Quinoline derivatives as tachykinin NK3 receptor antagonists | |
| HU9603342D0 (en) | Quinoline derivatives as leukotriene antagonists | |
| GB9711030D0 (en) | Quinoline leukrotriene antagonists | |
| HK1016582A (en) | Salts of quinoline derivatives as nk3 antagonists | |
| GB9402306D0 (en) | Quinoline derivatives | |
| IL139301A0 (en) | Quinoline derivatives | |
| GB9413937D0 (en) | Quinoline derivatives | |
| ZA969810B (en) | Novel quinoline derivatives. | |
| ZA969811B (en) | Novel quinoline derivatives. | |
| HK1018452A (en) | Tetrahydroquinoline derivatives as eaa antagonists |